The Food and Drug Administration (FDA) has approved Symbravo ® (meloxicam/rizatriptan) for the acute treatment of migraine with or without aura in adults.

The numbers are similarly impressive for other neurological disorders (i.e., dementias, Parkinson's disease, epilepsy, multiple sclerosis, motor neuron disease, headache disorders ... of individual ...

Fatigue was the most prevalent symptom (57%), followed by dry cough (50%) and headache (46%). The median (IQR) symptom duration was 10 (6–17) days but 14% reported symptoms >28 days. Median time loss ...